 Hi, I'm Dario Vinello. I'm the corresponding author of our recently published paper about our apophine service. Before diving deep into the details, our principal investigator, Prof. Prady Francisci, will tell you about the reason behind apophine development. Microfondal DNA is our second genome. It is very important and is involved in a variety of human diseases and in aging. And we analyzed microfondal DNA within the framework of many European projects. Now it is possible that the technology allows us to have the complete microfondal DNA sequences and apophine is the most robust, reliable and up-to-date tool to analyze microfondal DNA within a very short time. So this is phyliotree that represented the factor standard for human microfondal for the genetic trees. This is indeed just a small part of the tree, the beginning of phylus subtree. But it is sufficient to show you that there are a lot of different hyperglobes and some of them are defined by many, many mutations. So the work you need to do when you try to find out which is the best fit for a sample inside the tree is that you need to manually compare the list of the mutations your sample has with the mutations defined by no hyperglobes. This is obviously a very long work, a very error-prone work, so in the context of eye throughput projects you need an automatic way to do it. Automatic metals are indeed available, the first being HMTDB published in 2005, the last being HaproGraph published in 2010. However both have shortcomings, so we decided to build a completely new pipeline that we call apophine that tries to overcome those problems. Let me now walk you through our web application, this is apophine homepage, here you can find a short description of the service and what we call apophine quick start. Following those scenes you will be able to start finalizing your sample in our system in a matter of minutes. If you need additional help please check our frequently asked question page, here you can find answers to the most common problems. If it is not sufficient please go to our feedback page, we will be there to help you. I will show you now how to submit a new batch to be known as an apophine. First of all go to the submit form, enter your batch name, your email address, so please use a real email address, since apophine server needs to send you a couple of emails and then select the file containing your samples. Click the submit button and the system will start loading your sequence automatically. The system is now processing the sequences. The time needed to complete the process depends on manufacturers, the server workload, the network workload and the file size, so please be patient. Let's wait for a couple of seconds and these are the results. However this doesn't tell the whole story, I would like to show you now all the steps that apophine took to give you back the results. This is a schema of apophine pipeline, once a new batch is submitted for analysis the system starts loading it automatically. In the meantime an email is sent to the user containing a unique link to access the results. During the loading process each sequence analyzes queue independently allowing for parallel computation. Once the last sequence has been analyzed the system sends an email to the user informing him that the results are ready. Results are deleted after 24 hours for security reasons. Now let's go back to the web interface. This is the results page for the batch I've submitted before. As you can see for each sample you have the apropope assignment, the apropope score, the identified mutation and the flag that states if the assignment completed correctly or not. Clicking on each sample the system will load additional information about the assignment. It will obtain the list of the mutation, if they were expected or not, they identified the loci and known association with diseases. If you are not happy with the assignment that the apophine did you can easily change it through the assignment tree. Additional details regarding apropine design and implementation are available in the article. So have a nice reading and see you on Facebook or Twitter.